-
In this non-inferiority clinical trial, 1-year prophylaxis with an oral lactobacilli probiotic combination proved less effective than trimethoprim-sulfamethoxazole for preventing recurrence of urinary tract infections in postmenopausal women. However, although women in the antibiotic group had a dramatic increase in antibiotic resistance, there was no increase noted in the probiotic group.
-
Results of this year-long intervention trial suggest that an ethanolic extract of curcumin could, together with appropriate dietary and lifestyle changes, play a role in slowing the progression from prediabetes to type 2 diabetes.
-
CME Objectives/CME Questions
-
Adults treated with glucocorticoids in a primary care setting have a five-fold increase in suicide or suicidal behavior and other severe neuropsychiatric disorders. The risk is highest with first-time use of these medications.
-
The presence of aortic valve calcification (AVC) predicts cardiovascular and coronary event risk independent of traditional risk factors and inflammatory biomarkers, likely due to the strong correlation between AVC and subclinical atherosclerosis.
-
Clinical Briefs: Risk for Zoster from the Vaccine in Immunosuppressed Persons, Elucidating the Best, Cerebral Aneurysms: Whats in Your
Patients Future?
-
Off-label prescribing is common in primary care and most of the time lacks the scientific evidence to support it.
-
The ECG was obtained from a patient whose blood pressure was dropping. How many reasons can you cite to support a diagnosis of ventricular tachycardia (VT)?
-
THE FDA HAS APPROVED A SECOND WEIGHT-LOSS DRUG WITHIN the last month. This product is a combination of phentermine, an anorectic, and the antiepileptic topiramate. Phentermine/topiramate (PHEN/TPM) is manufactured by Catalent Pharma Solutions and marketed by Vivus Inc. as Qsymia.
-
The FDA has approved a new pancreatic enzyme preparation for the treatment of pancreatic insufficiency. Pancrelipase contains porcine derived lipases, proteases, and amylases. It is marketed by Aptalis Pharma U.S. Inc. as Viokace.
